We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Spinal Muscular Atrophy Foundation Announces Collaboration with PTC Therapeutics
News

Spinal Muscular Atrophy Foundation Announces Collaboration with PTC Therapeutics

Spinal Muscular Atrophy Foundation Announces Collaboration with PTC Therapeutics
News

Spinal Muscular Atrophy Foundation Announces Collaboration with PTC Therapeutics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Spinal Muscular Atrophy Foundation Announces Collaboration with PTC Therapeutics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Spinal Muscular Atrophy Foundation has announced that they have initiated a research and development collaboration with PTC Therapeutics, Inc. (PTC).

The collaboration is designed to leverage PTC’s proprietary Gene Expression Modulation by Small molecules (GEMS) technology to identify and develop small molecule therapeutics for use in the treatment or prevention of spinal muscular atrophy (SMA).

Under the terms of the agreement, the SMA Foundation will provide up to $1.6 million in funding to PTC based upon completion of certain milestones.

"PTC has demonstrated a strong commitment to SMA and other pediatric orphan diseases," said Loren Eng, President of the SMA Foundation.

"We believe PTC’s scientific assets and proven accomplishments make them an ideal partner in our efforts to identify treatments for SMA."

PTC’s GEMS technology exploits the regulatory mechanisms found in the untranslated regions of messenger RNA for the identification of small-molecule drugs that can treat diseases by selectively increasing or decreasing the expression of key proteins by modulating post-transcriptional mechanisms.

Another SMA Foundation research project will explore the application of PTC’s nonsense suppression compounds and technology to SMA.

Advertisement